News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3
Photo from Andres Gomez/Twitter
Nov 20, 2023, 03:53

Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3

Andres Gomez, Associate Professor at the Autonomous University of Nuevo León, Monterrey, Mexico, posted on X/Twitter:

“This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3 and why Yadith Lopez will present a poster comparing pre-post outcomes in the American Society of Hematology 23.

AML in India commentary The Lancet Haematology mirrors Mexico.”

Andres Gomez: This is why we developed a phase 2 study with outpatient ven-aza instead of 7+3

For the article click here.
Source: Andres Gomez/Twitter

American Society of Hematology AML Andres Gomez Autonomous University of Nuevo León cancer OncoDaily Oncology The Lancet Haematology Yadith Lopez
Special Coverage
Career
Jan 17, 2025, 16:19
OncoInfluencers to Follow on Social Media: Carolyn Taylor
Blog
Jan 17, 2025, 15:34
Cervical Cancer Awareness Month 2025: A Call to Action
Blog
Jan 17, 2025, 15:25
Douglas Flora: I'll be kicking off the NCI's new and groundbreaking "AI and Cancer Webinar Series"
Blog
Jan 17, 2025, 15:15
Great Debates and Updates in TNBC - BGICC 2025
Blog
Jan 17, 2025, 15:10
The countdown to World Cancer Day begins - European Liver Patients'​ Association
Blog
Jan 17, 2025, 15:06
Voice of the families, Girmave and his father - CANCaRe Africa
Blog
Jan 17, 2025, 15:03
Rawia Mohamed: Reflex molecular testing in cases of cholangiocarcinoma
Blog
Jan 17, 2025, 15:02
Cancer survivors across Europe face significant financial discrimination - European Cancer Organisation
Science
Jan 17, 2025, 14:52
Marcelo Negrao: Co-mutations and transcriptional signatures in non-small cell lung cancer patients
Science
Jan 17, 2025, 14:48
Bishal Gyawali: ESMO Global Consortium Study on the availability, affordability, and accessibility of cancers medicines
Blog
Jan 17, 2025, 14:44
Razelle Kurzrock: BRAF mutations are not one size fits all
Blog
Jan 17, 2025, 14:42
The Grand Opening Session of the 17th BGICC